Letermovir - Merck & Co

Drug Profile

Letermovir - Merck & Co

Alternative Names: AIC-001; AIC-090027; AIC-246; BAY-73-6327; MK-8228; PREVYMIS

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer Merck & Co
  • Class Acetates; Antivirals; Fluorobenzenes; Phenyl ethers; Piperazines; Quinazolines; Small molecules
  • Mechanism of Action Cytomegalovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cytomegalovirus infections

Most Recent Events

  • 08 Dec 2017 Launched for Cytomegalovirus infections (Prevention) in USA (IV,Injection) (Email communication with AiCuris)
  • 08 Dec 2017 Launched for Cytomegalovirus infections (Prevention) in USA (PO,tablet) (Email communication with AiCuris)
  • 13 Nov 2017 Merck expects decision from European commission on MAA of letermovir for Cytomegalovirus infections (Prevention) in January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top